ImmunityBio (IBRX) EBIAT (2016 - 2025)
Historic EBIAT for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$67.3 million.
- ImmunityBio's EBIAT rose 2154.82% to -$67.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$348.7 million, marking a year-over-year increase of 4068.64%. This contributed to the annual value of -$413.6 million for FY2024, which is 2915.24% up from last year.
- ImmunityBio's EBIAT amounted to -$67.3 million in Q3 2025, which was up 2154.82% from -$92.6 million recorded in Q2 2025.
- ImmunityBio's 5-year EBIAT high stood at -$59.2 million for Q4 2024, and its period low was -$233.4 million during Q4 2023.
- Its 5-year average for EBIAT is -$108.1 million, with a median of -$95.6 million in 2023.
- Per our database at Business Quant, ImmunityBio's EBIAT crashed by 18492.78% in 2021 and then soared by 7464.63% in 2024.
- ImmunityBio's EBIAT (Quarter) stood at -$91.6 million in 2021, then fell by 18.32% to -$108.3 million in 2022, then tumbled by 115.47% to -$233.4 million in 2023, then surged by 74.65% to -$59.2 million in 2024, then fell by 13.68% to -$67.3 million in 2025.
- Its EBIAT stands at -$67.3 million for Q3 2025, versus -$92.6 million for Q2 2025 and -$129.7 million for Q1 2025.